Multinational, observational and non-interventional study of 12 months to evaluate the effectiveness, tolerability and quality of life of brivaracetam as add-on therapy to previous lines of treatment in adult patients with a history of seizures
COMMERCIAL POST AUTHORIZATION STUDY
Clinical trial information
- Promoter: UCB BIOSCIENCES GMBH
- Execution start: 02/06/2021
- End of execution: 30/12/2023
- IP: JESUS ANTONIO RUIZ GIMENEZ